Home » Sophie Katz

Sophie Katz

Senior Manager

Sophie Katz was a Senior Manager at CBPartners.

Connect with Sophie Katz

sophie.katz@cbpartners.com

LinkedIn

Published Articles

The Future of Cell Therapy: What’s Next?

New cell therapy technologies show blockbuster potential for improved accessibility and efficacy in a wide range of indications, though these therapies come with their own downfalls that healthcare systems will need to adapt to in order for these products to reach their full potential.

CAR-Ts: Barriers and Opportunities for the Migration into Earlier Lines of Therapy in the USA

CAR-Ts offer a significant clinical benefit for patients, however their full potential is currently limited by later line use at sites that are mostly academic centers, combined with significant logistical barriers. In CBPartners’ latest thought leadership article, our healthcare consultants look further into these barriers before assessing the opportunities that could bring CAR-Ts into earlier lines of treatment across oncology.

Alzheimer’s and Aducanumab: The Beta Amyloid Theory’s Last Hope

What’s Next for Alzheimer’s Disease?

Basic science has been redeployed to establish a new understanding of Alzheimer's Disease, focusing on novel biomarkers and cutting-edge therapeutic approaches to slow or reverse disease progression, where the amyloid beta theory has otherwise failed

ISPOR Annual 2020: OCM to OCF: Implications for Total Cost of Care

A research poster that aims to map the limitations of the OCM to the proposed features of the 2021 OCF model in order to evaluate whether the OCF is more likely to successfully reduce total cost of care.

CBPartners’ Pharma Take-Away: Cell and Gene Therapy Roundtable

In this episode, our host Jared Wolff is joined by healthcare consultants Sophie Katz (a core member of CBPartners' Cell and Gene Therapy Center of Excellence), and Jay Galli to discuss some interesting topics surrounding cell and gene therapies.

CAR T-Cell Therapies: How Close Are We to Meeting the Remaining Needs of Patients?

In 2017, the first therapy designed to genetically modify patients’ own T-cells to attack cancer was FDA-approved, but are CAR T-cell therapies close to meeting the remaining needs of patients? CBPartners' Cell and Gene Therapy Center of Excellence investigates the current challenges and limitations of this therapy.